Triterpenoids Display Single Agent Anti-tumor Activity in a Transgenic Mouse Model of Chronic Lymphocytic Leukemia and Small B Cell Lymphoma
2007

Anti-tumor Effects of Triterpenoids in Leukemia

Sample size: 10 publication 10 minutes Evidence: high

Author Information

Author(s): Kress Christina L., Konopleva Marina, Martínez-García Vanesa, Krajewska Maryla, Lefebvre Sophie, Hyer Marc L., McQueen Teresa, Andreeff Michael, Reed John C., Zapata Juan M.

Primary Institution: Burnham Institute for Medical Research

Hypothesis

Can synthetic triterpenoids effectively reduce tumor burden in chronic lymphocytic leukemia (CLL) using a transgenic mouse model?

Conclusion

Synthetic triterpenoids CDDO and CDDO-Im significantly reduce leukemia and lymphoma burden in a transgenic mouse model of CLL.

Supporting Evidence

  • CDDO-Im was shown to be over 10-fold more potent than CDDO in inducing apoptosis.
  • Treatment with CDDO-Im resulted in over 90% reduction of B cells in blood.
  • CDDO-Im treatment caused little effect on normal B and T cells.

Takeaway

Researchers found that a special type of medicine made from plants can help fight a kind of blood cancer in mice.

Methodology

The study used transgenic mice with CLL to test the effects of CDDO and CDDO-Im on tumor cells both ex vivo and in vivo.

Potential Biases

Potential bias in the selection of treatment dosages and the interpretation of results.

Limitations

The study was conducted in a mouse model, which may not fully replicate human responses.

Participant Demographics

Transgenic mice with chronic lymphocytic leukemia.

Statistical Information

P-Value

0.0005

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0000559

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication